In Germany, Cannabis Insurance Claims Totaled €51 Million in the First Quarter

Insurance reimbursements for medicinal cannabinoid products in Germany increased in the first quarter of 2023, indicating that Europe’s largest economy is gradually expanding its cannabis business, which is already one of the largest in the world.

According to the most recent data from the German National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), reimbursements totaled approximately 50.9 million euros ($55.6 million) in the January-March quarter.

This is a 6.5% gain over the same period last year, but a little decrease over the fourth quarter of 2022.

Almost 99,000 prescriptions were filled in the quarter.

The dried-flower segment consisted of 21.1 million euros in sales.

Sales of finished pharmaceutical products, which include medications like Sativex and Epidolex, totaled 13.1 million euros.

According to Statistics Canada, medical cannabis sales in Canada’s regulated market totaled 98 million Canadian dollars ($72 million) in the same quarter.

However, Germany’s reimbursement data excludes private prescription sales, which are paid for by patients out of pocket.

That means medical cannabis sales in Germany exceeded 55.6 million euros, though the country does not have an exact figure.

Leave a Reply